Research programme: hepatitis C virus inhibitors - Progenics
Alternative Names: PRO 206Latest Information Update: 19 Jun 2020
Price :
$50 *
At a glance
- Originator Progenics Pharmaceuticals
- Class Small molecules
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 16 Jun 2020 Progenics Pharmaceuticals has been acquired by Lantheus Holdings
- 15 Mar 2012 Discontinued for Hepatitis C in USA (PO)
- 23 Nov 2011 Research programme: hepatitis C virus inhibitors - Progenics is available for licensing as of 09 Nov 2011. http://www.progenics.com